Table 1.
Characteristics and clinical outcomes of the study population.
| Characteristics of the Study Population | COVID-19 > 40 Years (1 January–10 May 2020) |
COPD-COVID-19 (1 January–10 May 2020) |
OR (95% CI) p-Value |
|---|---|---|---|
| N | 13.546 | 793 | |
| Age | |||
| Years (mean ± SD) | 66 ± 15 | 75 ± 12 | <0.001 |
| Sex | |||
| Female (%) | 53 | 17 | 0.18 (0.15–0.22) |
| Comorbidities | |||
| Ischemic heart disease (%) | 8.8 | 22.6 | 3.02 (2.53–3.60) |
| Heart failure (%) | 13.8 | 33.9 | 3.21 (2.75–3.75 |
| Cardiac arrhythmia (%) | 8.0 | 18.5 | 2.61 (2.16–3.15) |
| Diabetes mellitus (%) | 26.1 | 40.6 | 1.93 (1.67–2.24) |
| Arterial Hypertension (%) | 54.2 | 76.4 | 2.74 (2.32–3.24) |
| Dyslipidemia (%) | 15.4 | 20.2 | 1.39 (1.16–1.66) |
| Pulmonary embolism (%) | 2.2 | 5.2 | 2.46 (1.76–3.44) |
| Stroke (%) | 8.3 | 13.1 | 1.46 (1.18–1.81) |
| Smoking (%) | 13 | 33.9 | 3.43 (2.93–4.00) |
| Hospitalization (%) | 31.1 | 39.8 | 1.57 (1.35–1.82) |
| In-hospital mortality (%) | 3.4 | 9.3 | 2.93 (2.27–3.79) |